Masters of Longevity - The Pulse

Nature - Protocols21 Jul 2026
Large-scale genome structure interrogation via recombinase-mediated rearrangements of multiplexed prime edits in repetitive elements - Nature Protocols (Nature

Large-scale genome structure interrogation via recombinase-mediated rearrangements of multiplexed prime edits in repetitive elements - Nature Protocols

A step-by-step protocol describes combining prime editing and recombinase insertions into repetitive elements to enable massively multiplexed, programmable genome rearrangements and fitness mapping.

Key takeaways
  • Full protocol takes ~12–18 weeks to complete and requires intermediate to advanced expertise in genome editing.
  • Yet existing methods are limited by the low density of achievable modifications or the toxicity of methods.
  • This scale of genome editing has not previously been attainable and supports a wide range of studies.
Frontiers - Health21 Jul 2026
AIEfficacy and safety analysis of immune checkpoint inhibitors combined with chemotherapy in the treatment of advanced triple-negative breast cancer: an umbrella

Efficacy and safety analysis of immune checkpoint inhibitors combined with chemotherapy in the treatment of advanced triple-negative breast cancer: an umbrella meta-analysis

A comprehensive umbrella meta-analysis evaluates efficacy and multisystem safety of adding immune checkpoint inhibitors to chemotherapy for advanced triple-negative breast cancer.

Key takeaways
  • Globally, the incidence of TNBC has shown a steady increase ( 3 ).
  • This subgroup presents considerable therapeutic challenges and is characterized by a generally poor prognosis ( 4 , 5 ).
  • Characterized by the absence of estrogen receptor (ER).
MoL Event Pick
MedTech World Asia | Hong Kong 2026 (Hong Kong, Hong Kong)

MedTech World Asia | Hong Kong 2026

26. AUG 2026 - 28. AUG 2026 - Hong Kong, Hong KongSummit

Hong Kong summit connecting MedTech and HealthTech leaders, startups, investors, hospital executives, regulators and innovators across APAC healthcare innovation.

Nature - Biotechnology21 Jul 2026
Catalytic profiling of extracellular vesicles maps altered cancer metabolism (Nature - Biotechnology)

Catalytic profiling of extracellular vesicles maps altered cancer metabolism

Covers a programmable nanohybrid platform that profiles extracellular vesicle metabolites in native biofluids to map tumour metabolic changes and prognosis.

Key takeaways
  • Additional data that support the findings of this study are available from the corresponding author upon request.
  • View all journals Current technologies for measuring cancer metabolism have limited clinical utility.
  • Termed atomically configured catalytic hybrids for profiling extracellular vesicle metabolites (ACTIVE).
Frontiers - Health21 Jul 2026
AIDurable response to ALK inhibition in low-allele-frequency SPTBN1–ALK–rearranged gastric cancer followed by lineage plasticity–mediated resistance: a case repor

Durable response to ALK inhibition in low-allele-frequency SPTBN1–ALK–rearranged gastric cancer followed by lineage plasticity–mediated resistance: a case report

A case report describing durable tumor shrinkage from ALK inhibition in gastric cancer with a low-frequency SPTBN1–ALK fusion and later lineage-driven resistance.

Key takeaways
  • Tumor was negative for HER2 amplification, microsatellite instability, and PD-L1 expression.
  • Accompanied by expansion of TP53-mutant alleles and acquisition of additional genomic alterations.
  • Subsequent histologic transformation to small-cell neuroendocrine carcinoma was observed.